Sarcoma
Volume 2009 (2009), Article ID 575629, 5 pages
doi:10.1155/2009/575629
Case Report

Ifosfamide May Be Safely Used in Patients with End Stage Renal Disease on Hemodialysis

Sheron Latcha, Robert G. Maki, Gary K. Schwartz, and Carlos D. Flombaum

Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, USA

Received 1 May 2009; Revised 4 August 2009; Accepted 13 October 2009

Academic Editor: Beatrice Seddon

Copyright © 2009 Sheron Latcha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. F. Brennan, S. Singer, B. O'Sullivan, and R. G. Maki, “Sarcomas of the soft tissue and bone: soft tissue sarcoma,” in Cancer: Principles and Practice of Oncology, V. DeVita, Ed., pp. 1741–1794, Wolters Kluwer, Philadelphia, Pa, USA, 8th edition, 2008.
  2. K. H. Antman, “Chemotherapy of advanced sarcomas of bone and soft tissue,” Seminars in Oncology, vol. 19, no. 6, supplement 12, pp. 13–22, 1992.
  3. M. Furlanut and L. Franceschi, “Pharmacology of ifosfamide,” Oncology, vol. 65, supplement 2, pp. 2–6, 2003. View at Publisher · View at Google Scholar · View at PubMed
  4. T. Wagner, “Ifosamide clinical pharmacokinetics,” Clinical Pharmacokinetics, vol. 26, no. 6, pp. 439–456, 1994.
  5. V. Gilard, M. C. Malet-Martino, M. de Forni, U. Niemeyer, J. C. Ader, and R. Martino, “Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy,” Cancer Chemotherapy and Pharmacology, vol. 31, no. 5, pp. 387–394, 1993. View at Publisher · View at Google Scholar
  6. L. M. Allen, P. J. Creaven, and R. L. Nelson, “Studies on the human pharmacokinetics of isophosphamide,” Cancer Treatment Reports, vol. 60, no. 4, pp. 451–458, 1976.
  7. G. P. Kaijser, H. J. Keizer, J. H. Beijnen, A. Bult, and W. J. M. Underberg, “Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide,” Anticancer Research, vol. 16, no. 5, pp. 3247–3257, 1996.
  8. W. P. Brade, K. Herdrich, and M. Varini, “Ifosfamide-pharmacology, safety and therapeutic potential,” Cancer Treatment Reviews, vol. 12, no. 1, pp. 1–47, 1985. View at Publisher · View at Google Scholar
  9. L. D. Lewis and C. A. Meanwell, “Ifosfamide pharmacokinetics and neurotoxicity,” The Lancet, vol. 335, no. 8682, pp. 175–176, 1990. View at Publisher · View at Google Scholar
  10. C. A. Meanwell, A. E. Blake, K. A. Kelly, L. Honigsberger, and G. Blackledge, “Prediction of ifosfamide/mesna associated encephalopathy,” European Journal of Cancer and Clinical Oncology, vol. 22, no. 7, pp. 815–819, 1986. View at Publisher · View at Google Scholar
  11. M. P. Goren, R. K. Wright, C. B. Pratt, et al., “Dechlorethylation of ifosfamide and neurotoxicity,” The Lancet, vol. 2, pp. 1219–1220, 1986.
  12. L. Carlson, M. P. Goren, D. A. Bush, et al., “Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor,” Cancer Chemotherapy and Pharmacology, vol. 41, no. 2, pp. 140–146, 1998. View at Publisher · View at Google Scholar
  13. H. Sauer, K. Fuger, and M. Blumenstein, “Modulation of cytotoxicity of cytostatic drugs by hemodialysis in vitro and in vivo,” Cancer Treatment Reviews, vol. 17, no. 2-3, pp. 293–300, 1990. View at Publisher · View at Google Scholar
  14. R. Fiedler, F. Baumann, B. Deschler, and B. Osten, “Haemoperfusion combined with haemodialysis in ifosfamide intoxication,” Nephrology Dialysis Transplantation, vol. 16, no. 5, pp. 1088–1089, 2001.